US FDA found no increased risk of suicidal behaviour or ideation linked to GLP-1s (LLY, NOVOB DC), according to Bloomberg; has asked companies to remove warnings about potential risk from the medicines' labels

The FDA's findings regarding GLP-1 medications suggest that concerns about suicidal behavior linked to these drugs are unwarranted, which could lead to a more favorable perception and increased sales for manufacturers like Eli Lilly and Novo Nordisk.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

US New Home Sales MoM (Sep) M/M 3.8% vs. Exp. -13.8% (Prev. 20.5% )

Marathon Petroleum's (MPC) CEO says if crude was to go beneath USD 50/bbl it would be a point of concern for US producers

US FDA found no increased risk of suicidal behaviour or ideation linked to GLP-1s (LLY, NOVOB DC), according to Bloomberg; has asked companies to remove warnings about potential risk from the medicines' labels

Russia's Foreign Minister says they condemn subversive and external interference in the internal political process of Iran

ISA providers have stepped up their warnings over UK Chancellor Reeves's limits on cash ISAs, warning in "heated" talks with Treasury and HMRC officials today that the plans risk driving investors away from, rather than towards, the UK stock market

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

Removing the warnings from product labels may enhance market confidence and drive equity prices higher in the pharma sector, particularly for the related stocks.

Related headlines

The whole workspace, free to try.

Try it free